Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCV-07 for Oral Mucositis in Head and Neck Cancer
NCT00756951Phase 2Completed
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Sep 2008
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of golotimod in oral mucositis (OM) (3 arms), sponsored by SciClone Pharmaceuticals (Holdings) Limited. Primary endpoints: Safety and Tolerability at 7 weeks and Delay to Onset of Severe Oral Mucositis at 7 weeks. Started Sep 2008; status: completed.
02
Drugs
golotimod
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT00756951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00756951.